Dr. Daniel Liedtke to be appointed CEO of Hirslanden

Dr Liedtke, 48, joined Hirslanden in 2001 and has subsequently held several senior roles within the business. He was Deputy Director at Hirslanden Klinik St. Anna in Luzern, before becoming Hospital Director of Klinik Hirslanden in Zurich between 2008 to 2015. In 2015, he was appointed to the Hirslanden Executive Committee as Chief Operating Officer, playing an instrumental role in the successful leadership of the business including the implementation of the ongoing Hirslanden 2020 strategic programme. Dr Liedtke is an expert on the Swiss healthcare system and has a proven track record in the development of new business models in the clinical environment. The appointment follows a comprehensive assessment process led by Mediclinic International Executives and Board members, who were unanimous in their decision to appoint Dr Liedtke, and demonstrates the strength of senior management across the Group.

Under Dr Wiesinger’s leadership, Hirslanden expanded its footprint from 13 hospitals in 2007 to the current portfolio of 18 hospitals through a series of successful acquisitions, the latest being Klinik Linde in Biel and Clinique des Grangettes in Geneva. Hirslanden now operates four outpatient clinics and has expanded in the fields of radiology and radiotherapy to broaden the overall service offering to patients in Switzerland. During Ole Wiesinger's ten-year term in office, turnover increased from CHF 1091 million to CHF 1735 million, and the number of employees rose from 5224 to 9635 during the same period. Significant investment has been made to enhance the quality of patient care which, together with the support from doctors, clinical staff and other employees, has enabled Hirslanden to retain its leading position in the Swiss private healthcare market. Dr Wiesinger will continue to provide support to the business until the end of March 2019.

Commenting today, Dr Ronnie van der Merwe, Chief Executive Officer of Mediclinic International said:

"On behalf of Mediclinic International and Hirslanden, I would like to express my sincere thanks to Ole for the many years he has dedicated to Hirslanden and for his outstanding leadership of the business. We wish him every success in his future as he explores new opportunities. I am very pleased to welcome Dr Daniel Liedtke as the new CEO of Hirslanden. He has demonstrated an impressive track record and in-depth knowledge of our Swiss business and the local healthcare market. His detailed involvement in the current Hirslanden 2020 strategic programme and understanding of our core business makes him the ideal person to continue the implementation of the programme and lead the business. We welcome his enthusiastic and energetic approach on the Mediclinic International Executive Committee as we work together to deliver long term success across the Group."

Dr Ole Wiesinger, CEO of Hirslanden, commented:

"I look back on the successful career I have had at Hirslanden and I would like to take this opportunity to thank the many talented people who I have worked alongside, during my time at Hirslanden, especially our almost 10,000 employees and 2,000 doctors. I feel that now is the right time to begin a new chapter. It has always been important to me to give back some of the success and experiences from my career and I hope to do this in the future through seeking professional opportunities such as board of director mandates, teaching posts and continuing engagement in a number of charitable endeavors. I wish my

successor, Dr Daniel Liedtke, the same warm welcome inside and outside the company that I experienced and know from working closely with him for the past ten years that he is capable of achieving great success as CEO of Hirslanden.“

Dr Daniel Liedtke, COO of Hirslanden, commented:

"I am delighted to be taking on the role of Chief Executive Officer at Hirslanden, having spent 17 years working with the excellent team of doctors, clinical staff and employees, as Chief Operating Officer and in other roles. The team delivers best-in-class performance for patients every day, making Hirslanden not only the leading private healthcare group in Switzerland but recognised internationally for the quality of its clinical care. In the role, I will, as Ole has done successfully, seek to build on this position of strength as we navigate through the current regulatory environment and ensure the successful deployment of the Hirslanden 2020 strategic programme.“

About the Hirslanden Private Hospital Group

As of 31 March 2018, the Hirslanden Private Hospital Group comprises 17 hospitals in 11 cantons, many of which have an outpatient surgical centre and an Emergency department. The group also operates 4 outpatient clinics, 16 radiology institutes and 4 radiotherapy institutes. The group has around 1,680 affiliated doctors and 9,635 employees, of whom 461 are permanently employed doctors. Hirslanden is the leading private hospital group and the largest medical network in Switzerland. In the 2017/18 financial year, the group generated turnover of 1,735 million Swiss francs. Between 1.01.2018 and 31.03.2018 the group treated more than 102,903 patients, amounting to a total of 473,343 inpatient days. In insurance terms, the patient mix consists of 47.9% basic, 29.7% semi-private, and 22.4% private insured patients.

The Hirslanden Private Hospital Group is synonymous with first-class medical care provided by highly qualified medical specialists with years of experience. As a system provider, Hirslanden stands out from the rest of the market: interdisciplinary medical centres of expertise and specialised institutes enable it to offer the best possible individualised treatment, even in highly complex cases. The Hirslanden Private Hospital Group was formed in 1990 through the merger of several Swiss private hospitals. Since 2007 it has been part of the international hospital group Mediclinic International plc, which is listed on the London Stock Exchange.